Q3 2026 Coherus Oncology, Inc. Earnings Conference Call - COHERUS ONCOLOGY INC

Financial Performance:

• Q3 2026 net sales for Lactoris (Loftruzi) reached $14 million, representing 3% sequential growth and 25% year-over-year growth.
• Full-year 2026 revenue guidance revised to $54–$57 million (previously $15 million quarterly target for Q4), driven by slower new patient starts and market volatility.
• Cash and equivalents at Q3 2026 ended at $83.6 million, down $21.7 million from Q2, with cash burn of $34 million for the quarter (a 43% reduction from H1 2026 average).
• R&D expenses for Q3 2026 were $22.6 million (down from $27.3 million in Q3 2025); SG&A expenses were $21.2 million (down from $24.9 million in Q3 2025).
• Full-year 2026 combined operating expenses (OPEX) reiterated at $170–$175 million.
• Debt refinancing completed with a new $55 million term loan used to pay off a $38.7 million loan, generating a net $11.5 million cash influx; cash runway is under 12 months without new funding or cost cuts.
• Cost reduction initiatives (30% headcount reduction) are projected to save $6–$7 million per quarter, lowering the break-even revenue requirement for Lactoris from $30–$35 million to $25–$30 million quarterly.
• Udenica divestiture earn-out: Reported net sales are close to meeting the first $37.5 million milestone; audit rights exercised to verify results.

Guidance and Future Outlook:

• Strategic goal to achieve financial self-sustainability and break-even on core cash burn by the end of 2027.
• Lactoris peak market share expected by 2028, with long-term goal to dominate the Nasopharyngeal Carcinoma (NPC) space.
• Management plans to engage financial advisors to pursue ex-U.S. partnering deals for Tegno Keto (TAGMO) to offset clinical costs and fund accelerated approval.
• Immediate focus on aligning with the FDA on Recommended Phase 2 Dose (RP2D) and second-line esophageal cancer study design for potential accelerated approval.
• FDA meetings scheduled for Q1 2027 to finalize development strategy; data submission anticipated late Q1 or early Q2 2027.
• Long-term revenue target for Lactoris is to reach a dominant market share by displacing chemotherapy alone and off-label immunotherapies.

Business Segments and Product Lines:

• Lactoris (Loftruzi): Current market share approximately 20–22%; significant growth opportunity exists in converting the 30% of patients on chemotherapy alone and the 40% on off-label immunotherapies.
• TAGMO-Keto (Tegmo Ketoc): Strategic prioritization focused on esophageal cancer (both squamous cell carcinoma [ESCC] and adenocarcinoma [EACC]); other indications deprioritized to reduce burn.
• Second-Line Esophageal Data: Randomized study (TregCheck 102) at 700mg dose showed 33.3% confirmed ORR and 44.4% combined ORR, exceeding the ~10% chemotherapy benchmark; activity observed in PD-1 refractory and PD-L1 low/negative tumors.
• First-Line Esophageal Data: Interim data showed 89% ORR (100% in PD-L1 positive patients) with the TAGMO-Toripalimab doublet; safety profile manageable, with cisplatin-related renal toxicity identified as a mitigation target for future studies.
• Kesdozo (Kestoz):: Deprioritized but not abandoned; data maturation ongoing with expectation of dose-dependent activity similar to prior studies (e.g., initial ORR of 27% deepening to 38%).
• Combination Programs: T-cell engager combination studies are ongoing, leveraging immune-modulating potential of TAGMO.

Market and Competitive Landscape:

• Esophageal cancer is the 6th leading cause of cancer deaths globally (over 400,000 annual cases), creating a high unmet medical need, particularly in second-line settings where chemotherapy is the only standard of care.
• Current competitive landscape for second-line ESCC includes limited options; recent FDA approvals (e.g., toripalimab) criticized for not addressing PD-1 refractory patients adequately.
• Lactoris benefits from superior six-year survival data (64.8 months vs. 33.7 months for chemotherapy alone), driving a shift in physician sentiment.
• Physician survey indicates 75% view Lactoris as standard of care (vs. <35% for off-label IOs); 57% are aware of the six-year survival data.
• Competitive pressure exists from standard chemotherapy and off-label immunotherapies, but payer preference programs and clinical organization partnerships aim to accelerate adoption.

Risks and Challenges:

• Going Concern: Without new funding or cost reductions, cash runway is less than 12 months; financial viability relies on successful ex-U.S. partnering and Lactoris revenue growth.
• Clinical Execution: Dependency on successful FDA alignment for accelerated approval pathways; potential risks in defining contribution of effect in first-line studies.
• Market Dynamics: Lactoris faces "lumpiness" due to the rare nature of NPC and slow patient flow dynamics; risk of physician inertia in switching from chemotherapy to combination therapy.
• Regulatory Uncertainty: Future success hinges on FDA acceptance of ORR and durability endpoints for accelerated approval in esophageal cancer.
• Operational: Risks associated with the 30% headcount reduction and restructuring efforts.

Management Commentary and Tone:

• Tone is confident and decisive regarding the strategic pivot to esophageal cancer, emphasizing a "best-in-disease" opportunity with clear data support.
• Management expresses strong conviction in the ability to right-size the organization and achieve financial sustainability by 2027.
• Dr. Lanphier (CEO) highlighted the "substantial progress" in reducing debt and establishing Lactoris, while Dr. Diaz (CMO) emphasized the strength of the Treg depletion mechanism in overcoming immune resistance.
• Acknowledged Q3 revenue misses but attributed them to temporary market fluctuations rather than fundamental demand issues.
• Emphasis on "fast path to market" for TAGMO, leveraging FDA's Project Orbis and Project Frontrunner initiatives.

Analyst Questions and Answers:

• Regulatory Path (Paul Jeng): Confirmed precedent for combining histologies (squamous/adenocarcinoma) similar to Keynote-181; FDA has shown openness to ORR + durability for accelerated approval in this setting. First-line studies could proceed in parallel but second-line is prioritized for clarity on contribution of effect.
• Frontline Strategy (Jay Olson): Dr. LaValle noted need for mature data on durability and Clinical Benefit Rate (CBR) before FDA discussions for first-line; current focus remains on second-line randomized data.
• Revenue Leverage (Jay Olson): Sales growth strategies include targeting 30% of patients on chemo-only and 40% on off-label IOs via physician education, clinical organization partnerships, and payer preference programs.
• Combination Therapies (Mike Nedelkovit): T-cell engager combinations are active priorities; data from external studies (e.g., J&J) serves as benchmarks for safety and efficacy potential.
• Kesdozo Status (Mike Nedelkovit): Not deprioritized; data is maturing with expected deepening of response rates over time, similar to historical patterns.
• Study Design (Brian Chang): Next study is a randomized Phase 2 against chemotherapy in both histologies, aiming for accelerated approval based on ORR and duration (targeting 6-month duration metrics), with FDA meetings planned for Q1 2027.

Other Key Points:

• Manufacturing: Transfer of Toripalimab production from China to the U.S. completed; FDA action date for the drug product is November 30, 2026.
• Workforce Reduction: 30% headcount reduction (from ~140 to 100 FTEs) announced to align with the narrowed strategic focus, primarily cutting non-commercial functions.
• Ex-U.S. Partnering: Active discussions underway for international rights, leveraging Toripalimab's existing approval in Europe and other regions to share trial costs and accelerate global development.
• Clinical Trial Design: Plans to mitigate cisplatin-related renal toxicity in future studies by substituting with oxaliplatin.
• Upcoming Events: Management to attend Guggenheim and Jefferies conferences to discuss these strategic updates.